Quest Diagnostics (DGX) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenues reached $2.62 billion, up 14.5% year-over-year, with organic growth of 4.8%-5%; full-year revenue was $9.87 billion, up 6.7%-7%, with about 3% organic growth.

• Eight acquisitions completed in 2024, including LifeLabs in Canada and four U.S. hospital outreach labs, expanding advanced diagnostics and market reach.

• Investments in automation and AI improved quality, customer experience, and productivity, meeting annual 3% cost savings and productivity targets.

• Employee retention improved significantly, reinforcing position as an employer of choice.

• Quarterly dividend increased 6.7% to $0.80 per share, effective April 2025.

Financial highlights

• Q4 consolidated revenues were $2.62 billion (+14.5% YoY); full year: $9.87 billion (+6.7% YoY); organic revenues grew 4.8%-5%.

• Diagnostic information services revenues rose 15.1% YoY in Q4, driven by acquisitions and growth in physician and hospital channels.

• Q4 reported operating income was $361 million (13.8% margin); adjusted operating income was $409 million (15.6% margin).

• Q4 reported EPS was $1.95; adjusted EPS was $2.23, impacted by higher interest expense and tax rate.

• Full-year 2024 cash from operations was $1.33 billion, up from $1.27 billion in 2023; capital expenditures were $425 million.

Outlook and guidance

• 2025 net revenues expected between $10.70 billion and $10.85 billion, representing 8.4%-9.9% growth.

• 2025 reported EPS guidance: $8.34–$8.59; adjusted EPS: $9.55–$9.80.

• 2025 cash from operations projected at $1.45 billion; capital expenditures at $500 million.

• Revenue guidance assumes ~3% organic growth, with remainder from 2024 acquisitions; no contribution assumed from new 2025 M&A.

• Operating margin expected to expand in 2025; net interest expense projected at $275 million; adjusted tax rate at 25%.